Polymorphisms in type i and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil

Pharmacogenetics and Genomics

Volumn 20, Issue 9, 2010, Pages 537-543

  Gensburger, Olivier ^a,b   Van Schaik, Ron H N ^e   Picard, Nicolas ^a,b,c   Le Meur, Yannick ^d   Rousseau, Annick ^a,b   Woillard, Jean Baptiste ^a,b   Van Gelder, Teun ^e   Marquet, Pierre ^a,b,c  

^a INSERM   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d SERVICE DE RHUMATOLOGIE   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

inosine monophosphate dehydrogenase; mycophenolic acid; single nucleotide polymorphism; therapeutic drug monitoring

Indexed keywords

CALCINEURIN INHIBITOR; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG MONITORING; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOMEGALOVIRUS;

EID: 77955925612     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833d8cf5     Document Type: Article

References (35)

1. Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004; 18:485-492.
2. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60:225-232.
3. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345:1321-1325.
4. Allison A, Eugui E. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47:85-118.
5. Nowak I, Shaw LM. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity. Ther Drug Monit 1997; 19:358-360.
6. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17:681-684.
7. Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 1995; 49:1323-1329.
8. Wang W, Hedstrom L. Kinetic mechanism of human inosine 5-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. Biochemistry 1997; 36:8479-8483.
9. Gu JJ, Stegmann S, Gathy K, Murray R, Laliberte J, Ayscue L et al. Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene. J Clin Invest 2000; 106:599-606.
10. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34:429-455.
11. Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999; 65:640-648.
12. Weber LT, Shipkova M, Lamersdorf T, Niedmann PD,Wiesel M, Mandelbaum A, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998; 9:1511-1520.
13. Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7:2496-2503.
14. Van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86:1043-1051.
15. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008; 21:879-891.
16. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, et al. A novel variant L263F in human inosine 5-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007; 17:283-290.
17. Van Gelder T, Hesselink DA, van Hest RM, Mathot RA, van SR. Pharmacogenetics in immunosuppressive therapy: the best thing since TDM? Ther Drug Monit 2004; 26:343-346.
18. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008; 83:711-717.
19. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc 2004; 36:2787-2790.
20. Sanquer S, Maison P, Tomkiewicz C, Macquin-Mavier I, Legendre C, Barouki R, et al. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther 2008; 83:328-335.
21. Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 2008; 85:55-61.
22. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, et al. Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996; 85:921-930.
23. Colby TD, Vanderveen K, Strickler MD, Markham GD, Goldstein BM. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design. Proc Natl Acad Sci\USA 1999; 96:3531-3536.
24. Farazi T, Leichman J, Harris T, Cahoon M, Hedstrom L. Isolation and characterization of mycophenolic acid-resistant mutants of inosine-5- monophosphate dehydrogenase. J Biol Chem 1997; 272:961-965.
25. Mohamed MF, Frye RF, Langaee TY. Interpopulation variation frequency of human inosine 5-monophosphate dehydrogenase type II (IMPDH2) genetic polymorphisms. Genet Test 2008; 12:513-516.
26. Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG, et al. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T C polymorphism. Pharmacogenet Genomics 2009; 19:626-634.
27. Van Schaik RH, van Agteren M, de Fijter JW, Hartmann A, Schmidt J, Budde K, et al. UGT1A9-275T A/-2152C T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009; 86:319-327.
28. Djebli N, Picard N, Rerolle JP, Le Meur Y, Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics 2007; 17:321-330.
29. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 2009; 31:139-152.
30. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 2008; 85:1675-1685.
31. Armstrong VW, Shipkova M, Schutz E, Weber L, Tonshoff B, Oellerich M. Monitoring of mycophenolic acid in pediatric renal transplant recipients. Transplant Proc 2001; 33:1040-1043.
32. Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Ostrowska J, Gralak B, et al. The weight of pharmacokinetic parameters for mycophenolic acid in prediction of rejection outcome: the receiver operating characteristic curve analysis. Transplant Proc 2006; 38:86-89.
33. Takahashi K, Ochiai T, Uchida K, Yasumura T, Ishibashi M, Suzuki S, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee-Japan. Transplant Proc 1995; 27:1421-1424.
34. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13:759-768.
35. Weber LT, Shipkova M, Armstrong VW, Wagner N, Schutz E, Mehls O, et al. Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem 2002; 48:517-525.